ATE453620T1 - Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten - Google Patents

Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten

Info

Publication number
ATE453620T1
ATE453620T1 AT04730296T AT04730296T ATE453620T1 AT E453620 T1 ATE453620 T1 AT E453620T1 AT 04730296 T AT04730296 T AT 04730296T AT 04730296 T AT04730296 T AT 04730296T AT E453620 T1 ATE453620 T1 AT E453620T1
Authority
AT
Austria
Prior art keywords
treatment
receptor
mediated diseases
carboxamide derivatives
azetidine carboxamide
Prior art date
Application number
AT04730296T
Other languages
English (en)
Inventor
James Edward Paul Davidson
Claire Elizabeth Dawson
Kerry Harrison
Howard Langham Mansell
Robert Mark Pratt
Suhkjit Sohal
Victoria Jane Ruston
Original Assignee
Vernalis Res Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vernalis Res Ltd filed Critical Vernalis Res Ltd
Application granted granted Critical
Publication of ATE453620T1 publication Critical patent/ATE453620T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D205/00—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom
    • C07D205/02—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings
    • C07D205/04—Heterocyclic compounds containing four-membered rings with one nitrogen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/34—Tobacco-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Psychiatry (AREA)
  • Addiction (AREA)
  • Diabetes (AREA)
  • Psychology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Hospice & Palliative Care (AREA)
  • Emergency Medicine (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Rheumatology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT04730296T 2003-05-01 2004-04-29 Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten ATE453620T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB0310056 2003-05-01
PCT/GB2004/001831 WO2004096763A1 (en) 2003-05-01 2004-04-29 Azetidinecarboxamide derivatives and their use in the treatment of cb1 receptor mediated disorders

Publications (1)

Publication Number Publication Date
ATE453620T1 true ATE453620T1 (de) 2010-01-15

Family

ID=33397041

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04730296T ATE453620T1 (de) 2003-05-01 2004-04-29 Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten

Country Status (16)

Country Link
US (1) US7504522B2 (de)
EP (1) EP1620395B1 (de)
JP (1) JP2006525298A (de)
KR (1) KR20060010770A (de)
CN (1) CN1802350A (de)
AT (1) ATE453620T1 (de)
AU (1) AU2004234125A1 (de)
BR (1) BRPI0409938A (de)
CA (1) CA2524251A1 (de)
DE (1) DE602004024880D1 (de)
EA (1) EA010583B1 (de)
MX (1) MXPA05011670A (de)
NO (1) NO20055654L (de)
NZ (1) NZ543016A (de)
WO (1) WO2004096763A1 (de)
ZA (1) ZA200508831B (de)

Families Citing this family (46)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20060017763A (ko) * 2003-05-01 2006-02-27 베르날리스 리서치 리미티드 치료에 사용하는 아제티딘카르복스아미드 유도체의 용도
AU2004252109B2 (en) 2003-06-11 2010-04-08 Merck Sharp & Dohme Corp. Substituted 3-alkyl and 3-alkenyl azetidine derivatives
US20060025448A1 (en) 2004-07-22 2006-02-02 Cadila Healthcare Limited Hair growth stimulators
EP1902034B1 (de) 2005-06-02 2011-03-30 Glenmark Pharmaceuticals S.A. Neue cannabinoidrezeptorliganden, pharmazeutische zusammensetzungen, die diese enthalten, und verfahren zu ihrer herstellung
US7923465B2 (en) 2005-06-02 2011-04-12 Glenmark Pharmaceuticals S.A. Cannabinoid receptor ligands, pharmaceutical compositions containing them, and process for their preparation
US7906652B2 (en) 2005-11-28 2011-03-15 Merck Sharp & Dohme Corp. Heterocycle-substituted 3-alkyl azetidine derivatives
JP2009528999A (ja) * 2006-02-21 2009-08-13 アンプラ ファーマシューティカルズ インコーポレイテッド Ｃｂ１アンタゴニストおよび逆アゴニスト
BRPI0715160A2 (pt) 2006-08-08 2013-06-11 Sanofi Aventis imidazolidina-2,4-dionas substituÍdas por arilamimoaril-alquil-, processo para preparÁ-las, medicamentos compeendendo estes compostos, e seu uso
EP2025674A1 (de) 2007-08-15 2009-02-18 sanofi-aventis Substituierte Tetrahydronaphthaline, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
AR069700A1 (es) * 2007-12-18 2010-02-10 Sanofi Aventis Derivados de azetidina,composiciones farmaceuticas que los comprenden, metodo de preparacion, intermediarios de sintesis,y usos de los mismos en el tratamiento o prevencion de trastornos psiquiatricos , del sistema inmune y gastrointestinales, entre otros.
FR2925051B1 (fr) * 2007-12-18 2010-05-21 Sanofi Aventis Derives d'azetidines,leur preparation et leur application en therapeutique
WO2009157006A1 (en) * 2008-06-26 2009-12-30 Micro Labs Limited Process of preparing ebastine
WO2010003624A2 (en) 2008-07-09 2010-01-14 Sanofi-Aventis Heterocyclic compounds, processes for their preparation, medicaments comprising these compounds, and the use thereof
EP2348857B1 (de) 2008-10-22 2016-02-24 Merck Sharp & Dohme Corp. Neue cyclische benzimidazolderivate als antidiabetika
JP5557845B2 (ja) 2008-10-31 2014-07-23 メルク・シャープ・アンド・ドーム・コーポレーション 糖尿病用剤として有用な新規環状ベンゾイミダゾール誘導体
WO2010068601A1 (en) 2008-12-08 2010-06-17 Sanofi-Aventis A crystalline heteroaromatic fluoroglycoside hydrate, processes for making, methods of use and pharmaceutical compositions thereof
DK2470552T3 (en) 2009-08-26 2014-02-17 Sanofi Sa NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
AU2011218830B2 (en) 2010-02-25 2014-07-24 Merck Sharp & Dohme Corp. Novel cyclic benzimidazole derivatives useful anti-diabetic agents
US8933024B2 (en) 2010-06-18 2015-01-13 Sanofi Azolopyridin-3-one derivatives as inhibitors of lipases and phospholipases
MX348131B (es) 2011-02-25 2017-05-26 Merck Sharp & Dohme Novedosos derivados de azabencimidazol ciclico utiles como agentes antidiabeticos.
US8710050B2 (en) 2011-03-08 2014-04-29 Sanofi Di and tri- substituted oxathiazine derivatives, method for the production, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
WO2012120058A1 (de) 2011-03-08 2012-09-13 Sanofi Mit benzyl- oder heteromethylengruppen substituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120050A1 (de) 2011-03-08 2012-09-13 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
US8809325B2 (en) 2011-03-08 2014-08-19 Sanofi Benzyl-oxathiazine derivatives substituted with adamantane and noradamantane, medicaments containing said compounds and use thereof
EP2683704B1 (de) 2011-03-08 2014-12-17 Sanofi Verzweigte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
WO2012120054A1 (de) 2011-03-08 2012-09-13 Sanofi Di- und trisubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2683703B1 (de) 2011-03-08 2015-05-27 Sanofi Neue substituierte phenyl-oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2012120056A1 (de) 2011-03-08 2012-09-13 Sanofi Tetrasubstituierte oxathiazinderivate, verfahren zu deren herstellung, ihre verwendung als medikament sowie sie enthaltendes arzneimittel und deren verwendung
EP2766349B1 (de) 2011-03-08 2016-06-01 Sanofi Mit carbozyklen oder heterozyklen substituierte oxathiazinderivate, verfahren zu deren herstellung, diese verbindungen enthaltende arzneimittel und deren verwendung
WO2014022528A1 (en) 2012-08-02 2014-02-06 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
WO2014130608A1 (en) 2013-02-22 2014-08-28 Merck Sharp & Dohme Corp. Antidiabetic bicyclic compounds
WO2014139388A1 (en) 2013-03-14 2014-09-18 Merck Sharp & Dohme Corp. Novel indole derivatives useful as anti-diabetic agents
EP3013958B1 (de) * 2013-06-25 2019-12-25 The United States of America, as represented by the Secretary, Department of Health and Human Services Glucan-gekapselte sirna zur behandlung von diabetes mellitus vom typ 2
WO2015051496A1 (en) 2013-10-08 2015-04-16 Merck Sharp & Dohme Corp. Antidiabetic tricyclic compounds
CN105218474B (zh) * 2015-10-22 2017-12-05 山东国邦药业股份有限公司 (4r,5r)‑2‑二氯甲基‑4,5‑二氢‑5‑(4‑甲砜基苯基)‑4‑恶唑甲醇的合成方法
EP3452036A4 (de) 2016-05-04 2019-11-06 Inmed Pharmaceuticals Inc. Verwendung von topischen formulierungen von cannabinoiden bei der behandlung von epidermolysis bullosa und zugehörigen bindegewebserkrankungen
US11072602B2 (en) 2016-12-06 2021-07-27 Merck Sharp & Dohme Corp. Antidiabetic heterocyclic compounds
EP3684353A4 (de) 2017-09-22 2021-06-23 Inmed Pharmaceuticals Inc. Topische formulierungen von cannabinoiden und ihre verwendung zur schmerzbehandlung
WO2019134985A1 (en) 2018-01-08 2019-07-11 F. Hoffmann-La Roche Ag Octahydropyrido[1,2-alpha]pyrazines as magl inhibitors
EP3669876A1 (de) 2018-12-18 2020-06-24 Aelis Farma 3beta-(benzyloxy)-17alpha-methyl-pregn-5-en-20-on zur verwendung bei der behandlung kognitiver störungen
CR20230115A (es) * 2020-09-03 2023-04-11 Hoffmann La Roche Compuestos heterocíclicos
US11141404B1 (en) * 2020-11-18 2021-10-12 Anebulo Pharmaceuticals, Inc. Formulations and methods for treating acute cannabinoid overdose
AU2022362107A1 (en) * 2021-10-11 2024-05-02 Anebulo Pharmaceuticals, Inc. Crystalline forms of a cannabinoid receptor type 1 (cb1) modulator and methods of use and preparation thereof
AU2023351188A1 (en) * 2022-09-26 2025-04-17 Anebulo Pharmaceuticals, Inc. Treatment of acute cannabinoid overdose
WO2025090587A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Cannabinoids compounds and their use in the treatment of neuronal disorders
WO2025090133A1 (en) 2023-10-23 2025-05-01 Inmed Pharmaceuticals Inc. Compositions and methods for use of cannabinol compounds in neuroprotection

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4261990A (en) * 1979-03-09 1981-04-14 Ciba-Geigy Corporation N-alkyleneiminoalkyl-dicarboximides as antiallergics and antiasthmatics
JPH03264562A (ja) * 1989-05-22 1991-11-25 Hokuriku Seiyaku Co Ltd ピペリジン誘導体
JP3194355B2 (ja) * 1996-10-24 2001-07-30 宇部興産株式会社 ピペリジン化合物及びその製法
ES2207171T3 (es) 1998-01-23 2004-05-16 Vernalis Research Limited Derivados de azetidina carboxamida para tratar trastornos del sistema nervioso central.
GB9917386D0 (en) * 1999-07-23 1999-09-22 Cerebrus Ltd Chemical compounds-II
US6566356B2 (en) * 2000-03-03 2003-05-20 Aventis Pharma S.A. Pharmaceutical compositions containing 3-aminoazetidine derivatives, novel derivatives and their preparation
KR20060017763A (ko) * 2003-05-01 2006-02-27 베르날리스 리서치 리미티드 치료에 사용하는 아제티딘카르복스아미드 유도체의 용도

Also Published As

Publication number Publication date
WO2004096763A1 (en) 2004-11-11
EA010583B1 (ru) 2008-10-30
US7504522B2 (en) 2009-03-17
KR20060010770A (ko) 2006-02-02
CA2524251A1 (en) 2004-11-11
MXPA05011670A (es) 2005-12-15
CN1802350A (zh) 2006-07-12
EP1620395B1 (de) 2009-12-30
NO20055654D0 (no) 2005-11-30
NZ543016A (en) 2009-03-31
EA200501585A1 (ru) 2006-06-30
EP1620395A1 (de) 2006-02-01
AU2004234125A1 (en) 2004-11-11
BRPI0409938A (pt) 2006-04-25
ZA200508831B (en) 2007-03-28
US20070054891A1 (en) 2007-03-08
NO20055654L (no) 2006-01-31
JP2006525298A (ja) 2006-11-09
DE602004024880D1 (de) 2010-02-11

Similar Documents

Publication Publication Date Title
DE602004024880D1 (de) Azetidincarboxamid-derivate zur verwendung zur behandlung von cb1-rezeptor-vermittelten krankheiten
EA200970326A1 (ru) Алкильные производные в качестве метаботропных рецепторов глутамата
MY142807A (en) Benzimidazole derivative and use thereof.
IL176547A0 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives having cb1-antagonistic activity
SE0303180D0 (sv) Novel compounds
SE0302232D0 (sv) Novel Compounds
ATE384058T1 (de) Thiazolderivate
ATE437872T1 (de) Proteinkinaseinhibitoren
ATE398449T1 (de) Verwendung von azetidincarboxamidderivaten in therapie
ATE452896T1 (de) C3-cyanoepothilonderivate
IL195016A0 (en) 1h-indol-5-yl-piperazin-1-yl-methanone derivatives
ATE512142T1 (de) Pyrimidin- und chinazolinderivate als modulatoren der somatostatin-rezeptor aktivität
TW200716547A (en) Piperidin-4-yl-amide derivatives
EA200870074A1 (ru) Производные 4,5-дигидро-(1н)-пиразола в качестве модуляторов каннабиноидного рецептора св1
MX2007004910A (es) Nuevos derivados de indol o benzimidazol.
DE602006014022D1 (de) 5-substituierte indol-2-carbonsäureamidderivate
TW200635911A (en) Sulfanyl substituted phenyl methanones
DE60224509D1 (de) Imidazolderivate verwendbar als histamin h3 rezeptorliganden
DK1756066T3 (da) Tetrasubstituerede imidazolderivater som canabinoid-CB1-receptormodulatorer med höj CB1/CB2-receptorundertypeselektivitet
MX2008002753A (es) Derivados de piridazinona utilizados para el tratamiento de dolor.
UA84594C2 (en) 1,3,5-trisubstituted 4,5-dihydro-1h-pyrazole derivatives as cb1 antagonists

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties